Literature DB >> 12658915

[Dual infection with hepatitis B and C. Spontaneous course and response to virostatic therapy in children following neoplastic diseases].

Andrea Moser1, Herwig Lackner, Johann Deutsch, Reinhold Kerbl, Wolfgang Schwinger, Hans Jürgen Dornbusch, Harald H Kessler, Christian Urban.   

Abstract

UNLABELLED: Combined chronic hepatitis B and C is a long-term complication in children surviving malignancy. We report on seven children who acquired hepatitis B as well as C virus infection during treatment for different malignancies. Four patients showed a spontaneous HBe Ag/anti-HBe seroconversion, two patients spontaneous clearance of hepatitis C virus, and one patient showed both HBe Ag/anti-HBe seroconversion and clearance of hepatitis C virus. One patient developed HBe Ag/anti-HBe seroconversion after antiviral interferon monotherapy and another patient after combination therapy with interferon/famcyclovir. Three patients developed complete sustained response of hepatitis C to a combined virostatic therapy with interferon and ribavirin. A total of 4 of 7 patients had a clearance of both infections and 3 of 7 patients had a clearance of at least one infection.
CONCLUSION: Our data in long-term survivors of childhood cancer with combined hepatitis B and C showed a remarkably high rate of spontaneous cure and a favourable response to antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12658915     DOI: 10.1007/BF03040276

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  29 in total

1.  Effects of storage and type of blood collection tubes on hepatitis C virus level in whole blood samples.

Authors:  H H Kessler; E Stelzl; R B Raggam; J Haas; F Kirchmeir; K Hegenbarth; E Daghofer; B I Santner; E Marth; R E Stauber
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

2.  Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

Authors:  S W Schalm; B E Hansen; L Chemello; A Bellobuono; J T Brouwer; O Weiland; L Cavalletto; R Schvarcz; G Ideo; A Alberti
Journal:  J Hepatol       Date:  1997-05       Impact factor: 25.083

Review 3.  Therapy of hepatitis C: alpha interferon and ribavirin.

Authors:  O Reichard; R Schvarcz; O Weiland
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

4.  Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening.

Authors:  M Vogt; T Lang; G Frösner; C Klingler; A F Sendl; A Zeller; B Wiebecke; B Langer; H Meisner; J Hess
Journal:  N Engl J Med       Date:  1999-09-16       Impact factor: 91.245

5.  Detection of replicative form of hepatitis C virus RNA in peripheral blood mononuclear cells.

Authors:  J T Wang; J C Sheu; J T Lin; T H Wang; D S Chen
Journal:  J Infect Dis       Date:  1992-11       Impact factor: 5.226

6.  [Chronic hepatitis B. Treatment in childhood with alpha-interferon].

Authors:  S Wirth; E Sokal; E Schaefer; J Pohlenz; K M Keller
Journal:  Monatsschr Kinderheilkd       Date:  1992-10       Impact factor: 0.323

7.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

Authors:  C L Lai; R N Chien; N W Leung; T T Chang; R Guan; D I Tai; K Y Ng; P C Wu; J C Dent; J Barber; S L Stephenson; D F Gray
Journal:  N Engl J Med       Date:  1998-07-09       Impact factor: 91.245

8.  Interferon treatment in children with chronic hepatitis B.

Authors:  M Ruíz-Moreno
Journal:  J Hepatol       Date:  1995       Impact factor: 25.083

9.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

Review 10.  Famciclovir: review of clinical efficacy and safety.

Authors:  R Cirelli; K Herne; M McCrary; P Lee; S K Tyring
Journal:  Antiviral Res       Date:  1996-03       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.